Docetaxel

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Docetaxel, a new taxoid family member originally derived from the needles of the European Yew tree Taxus baccata, is a potent chemotherapeutic agent that acts as a spindle poison to inhibit microtubule dynamics and cell cycle arrest through promoting microtublin assembly and stabilizing the polymers against depolymerization. Docetaxel has demonstrated strong in vivo and in vitro antitumor activities against a broad range of cancers including breast, lung, ovarian, head and neck, and gastric cancers. Previous studies have shown that docetaxel exertss stronger cytotoxicity than other chemotherapeutic agents against ovarian carcinoma cell lines, in which the cytotoxicity of docetaxel is 1.2-2.6 times greater than that of paclitaxel and over 1000 times greater than that of cisplatin or etoposide.
- Properties
  - Alternative Name
    
    Taxotere, Docetaxel anhydrous, Trihydrate
    
    CAS Number
    
    114977-28-5
    
    Molecular Formula
    
    C43H53NO14
    
    Molecular Weight
    
    807.88
    
    Appearance
    
    A solid
    
    Purity
    
    99.12%
    
    Solubility
    
    ≥40.4 mg/mL in DMSO; insoluble in H2O; ≥94.4 mg/mL in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Weibo Zhong, Kaihui Wu, et al. "Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis." Microbiome. 2022 Jun 16;10(1):94. PMID: 35710492
    2. Mikhail S. Chesnokov, Marianna Halasi, et al. "Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells." Cell Death Dis. 2021 Jul 14;12(7):704. PMID: 34262016
    3. Robert Craig Peery. "Optimization of Survivin Dimerization Inhibitors for the Treatment of Docetaxel-Resistant Prostate Cancer." January 2020.
    4. Yan L, Ding B, et al. "Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma." Theranostics. 2019 Oct 22;9 (26):8377-8391. PMID: 31754403
    5. Zhang Y, Xia F, et al. "miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2." J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. PMID: 30665445
    6. Li Q, Deng Q, et al. "Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses." Nat Commun. 2018 Sep 6;9(1):3600. PMID: 30190514
    7. Zhou XW, Xia YZ, et al. "Tomentodione M sensitizes multidrug resistant cancer cells by decreasing P-glycoprotein via inhibition of p38 MAPK signaling. Oncotarget." 2017 Oct 19;8(60):101965-101983. PMID: 29254218

Docetaxel

Background

We Also Recommend

10-DAB (10-Deacetylbaccatin)

BMS 299897